Cellular crescents
Glomerular fibrinoid necrosis at Jones methenamine silver (JMS) staining
Furuta S, Jayne DRW. Antineutrophil cytoplasm antibody-associated vasculitis: Recent developments. Kidney Int 2013; 84:244−249. doi: 10.1038/ki.2013.24
Halbwachs L, Lesavre P. Endothelium-neutrophil interactions in ANCA-associated diseases. J Am Soc Nephrol 2012; 23:1449−1461. doi: 10.1681/ASN.2012020119
Jayne DRW, et al.. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 2017; 28:2756−2767. doi: 10.1681/ASN.2016111179
Jayne DRW, et al.. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 2021; 384:599−609. doi: 10.1056/NEJMoa2023386
Walsh M, et al.. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 2020; 382:622−631. doi: 10.1056/NEJMoa1803537
Kronbichler A, et al.. Frequency, risk factors and prophylaxis of infection in ANCA‐associated vasculitis. Eur J Clin Invest 2015; 45:346−368. doi: 10.1111/eci.12410
Flossmann O, et al.. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011; 70:488−494. doi: 10.1136/ard.2010.137778
Robson J, et al.. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: Long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford) 2015; 54:471−481. doi: 10.1093/rheumatology/keu366
McGregor JAG, et al.. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol 2012; 7:240−247. doi: 10.2215/CJN.05610611
Goupil R, et al.. Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. Clin J Am Soc Nephrol 2013; 8:416−423. doi: 10.2215/CJN.07300712
Charlier C, et al.. Risk factors for major infections in Wegener granulomatosis: Analysis of 113 patients. Ann Rheum Dis 2009; 68:658−663. doi: 10.1136/ard.2008.088302
Smith RM, et al.. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis 2020; 79:1243−1249. doi: 10.1136/annrheumdis-2019-216863
Jayne D, et al.. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36−44. doi: 10.1056/NEJMoa020286
de Groot K, et al.. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial. Ann Intern Med 2009; 150:670−680. doi: 10.7326/0003-4819-150-10-200905190-00004
Guillevin L, et al.. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014; 371:1771−1780. doi: 10.1056/NEJMoa1404231
Charles P, et al.. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 2018; 77:1143−1149. doi: 10.1136/annrheumdis-2017-212878
Charles P, et al.. Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial. Ann Intern Med 2020; 173:179−187. doi: 10.7326/M19-3827
Smith RM, et al.. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis 2020; 79:1243−1249. doi: 10.1136/annrheumdis-2019-216863
Smith R, et al.. A randomized, controlled trial of rituximab versus azathioprine after induction of remission with rituximab for patients with ANCA-associated vasculitis and relapsing disease. Nephrol Dial Transplant 2020; 35 (Suppl 3):LB004. doi: 10.1093/ndt/gfaa146.LB004
Smith R, et al.. A randomized, controlled trial of rituximab versus azathioprine after induction of remission with rituximab for patients with ANCA-associated vasculitis and relapsing disease [abstract]. Arthritis Rheumatol 2019; 71 (Suppl 10):806. https://acrabstracts.org/abstract/a-randomized-controlled-trial-of-rituximab-versus-azathioprine-after-induction-of-remission-with-rituximab-for-patients-with-anca-associated-vasculitis-and-relapsing-disease/